Screening, enrollment and retention
genital/reproductive tract infections
SEXUALLY TRANSMITTED INFECTIONS, URINARY TRACT INFECTIONS
Participants were screened for eligibility prior to enrolling in the study. All enrolled participants provided written informed consent. Participants returned to the clinic within the 45-day screening window where they completed administrative, behavioral, clinical, and laboratory procedures. Additionally, clinical results or treatments for urinary tract infections, genital/reproductive tract infections, sexually transmitted infections (UTIs/RTIs/STIs) or other findings were provided as clinically indicated at all visits. At all clinic visits, participants were also dispensed condoms and lubricant. Consented and enrolled participants were then randomized into one of six sequences, each varying the order in which participants used the study placebo products, with a 1-week wash-out period between each 4-week product use period (